Analysts think INDP stock price could increase by 388%
Jul 31, 2024, 6:27 AM
-20.57%
What does INDP do
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company based in New York City, specializes in developing immunotherapy for unresectable or metastatic solid tumors and lymphomas. Their leading candidate, Decoy20, targets tumor and viral antigens using a platform that activates both innate and adaptive cellular immunity, delivered intravenously to target organs and tumors.
4 analysts think INDP stock price will increase by 388.04%. The current median analyst target is $10.20 compared to a current stock price of $2.09. The lowest analysts target is $8.08 and the highest analyst target is $12.60.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
